LEADER 03586nam  22006735  450 
001 9910300096803321
005 20210322174336.0
010   $a1-4471-5472-X
024 7 $a10.1007/978-1-4471-5472-3
035   $a(CKB)3710000000073724
035   $a(EBL)1592860
035   $a(SSID)ssj0001067244
035   $a(PQKBManifestationID)11612776
035   $a(PQKBTitleCode)TC0001067244
035   $a(PQKBWorkID)11097044
035   $a(PQKB)10554283
035   $a(MiAaPQ)EBC1592860
035   $a(DE-He213)978-1-4471-5472-3
035   $a(PPN)176096949
035   $a(EXLCZ)993710000000073724
100   $a20131121d2014      u|             0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 10$aCardiac Drugs in Pregnancy$b[electronic resource] /$fedited by Karen Sliwa, John Anthony
205   $a1st ed. 2014.
210  1$aLondon :$cSpringer London :$cImprint: Springer,$d2014.
215   $a1 online resource (141 p.)
225 1 $aCurrent Cardiovascular Therapy
300   $aDescription based upon print version of record.
311   $a1-4471-5471-1 
327   $aIntroduction -- General principles and guidelines -- Management of Hypertension -- Management of Heart Failure -- Management of  coronary artery disease & Arrhythmia -- Anticoagulation in Pregnancy -- Obstetric drugs in management if Cardiovascular disease -- Pregnancy anaesthesia in patients with cardiovascular disease.
330   $aIn the western world, the risk of cardiovascular disease in pregnancy has grown due to the increasing age at the first pregnancy and the worldwide obesity epidemic leading to early diabetes and hypertension. As a result more women are requiring drug therapy during pregnancy  and some data has shown an altered pharmacodynamic profile in pregnant women when compared to the non-pregnant population. Cardiac Drugs in Pregnancy presents up-to-date research for the treatment of cardiovascular disease during pregnancy, and  discusses the most important indications of drug usage in pregnancy and postpartum. The book aims to assess the potential risk of drugs and their possible benefit against each other, making it an essential read for a wide range of health professionals involved in cardiac drug therapy in pregnancy.
410  0$aCurrent Cardiovascular Therapy
606   $aCardiology
606   $aObstetrics
606   $aMaternal and child health services
606   $aPharmacotherapy
606   $aCardiology$3https://scigraph.springernature.com/ontologies/product-market-codes/H33037
606   $aObstetrics/Perinatology/Midwifery$3https://scigraph.springernature.com/ontologies/product-market-codes/H26014
606   $aMaternal and Child Health$3https://scigraph.springernature.com/ontologies/product-market-codes/H27025
606   $aPharmacotherapy$3https://scigraph.springernature.com/ontologies/product-market-codes/H69000
615  0$aCardiology.
615  0$aObstetrics.
615  0$aMaternal and child health services.
615  0$aPharmacotherapy.
615 14$aCardiology.
615 24$aObstetrics/Perinatology/Midwifery.
615 24$aMaternal and Child Health.
615 24$aPharmacotherapy.
676   $a616.1061
702   $aSliwa$b Karen$4edt$4http://id.loc.gov/vocabulary/relators/edt
702   $aAnthony$b John$c(Professor of obstetrics and gynecology).$4edt$4http://id.loc.gov/vocabulary/relators/edt
906   $aBOOK
912   $a9910300096803321
996   $aCardiac Drugs in Pregnancy$91522055
997   $aUNINA